AbbVie Inc. (NYSE:ABBV) Holdings Raised by TFR Capital LLC.

TFR Capital LLC. grew its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 15.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,222 shares of the company's stock after buying an additional 2,038 shares during the quarter. AbbVie accounts for 1.3% of TFR Capital LLC.'s portfolio, making the stock its 19th largest position. TFR Capital LLC.'s holdings in AbbVie were worth $3,189,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in ABBV. EnRich Financial Partners LLC raised its position in AbbVie by 196.4% in the fourth quarter. EnRich Financial Partners LLC now owns 166 shares of the company's stock worth $29,000 after acquiring an additional 110 shares during the period. Abound Financial LLC bought a new position in AbbVie in the first quarter worth approximately $30,000. Prudent Man Investment Management Inc. bought a new position in AbbVie in the fourth quarter worth approximately $32,000. Siemens Fonds Invest GmbH raised its position in AbbVie by 197.6% in the fourth quarter. Siemens Fonds Invest GmbH now owns 179,440 shares of the company's stock worth $32,000 after acquiring an additional 119,141 shares during the period. Finally, Pinney & Scofield Inc. bought a new position in AbbVie in the fourth quarter worth approximately $36,000. Hedge funds and other institutional investors own 70.23% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on ABBV shares. The Goldman Sachs Group restated a "neutral" rating and set a $194.00 price objective on shares of AbbVie in a research report on Tuesday, April 8th. Erste Group Bank upgraded shares of AbbVie to a "strong-buy" rating in a research report on Monday, March 17th. BNP Paribas upgraded shares of AbbVie to a "hold" rating in a research report on Thursday, May 8th. Evercore ISI raised their price objective on shares of AbbVie from $204.00 to $205.00 and gave the company an "outperform" rating in a research report on Monday, April 28th. Finally, Bank of America raised their price objective on shares of AbbVie to $204.00 and gave the company a "hold" rating in a research report on Monday, June 9th. Eight investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $211.29.

AbbVie Trading Down 0.8%

NYSE ABBV traded down $1.51 during mid-day trading on Monday, hitting $190.94. The company's stock had a trading volume of 1,067,732 shares, compared to its average volume of 6,291,330. AbbVie Inc. has a 52-week low of $163.81 and a 52-week high of $218.66. The stock's fifty day simple moving average is $187.01 and its two-hundred day simple moving average is $189.11. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.76 and a quick ratio of 0.64. The firm has a market capitalization of $337.28 billion, a P/E ratio of 81.23, a price-to-earnings-growth ratio of 1.28 and a beta of 0.48.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.40 by $0.06. The company had revenue of $13.34 billion for the quarter, compared to analyst estimates of $12.91 billion. AbbVie had a net margin of 7.31% and a return on equity of 412.03%. The business's quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the firm posted $2.31 earnings per share. Research analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be issued a $1.64 dividend. This represents a $6.56 dividend on an annualized basis and a yield of 3.44%. The ex-dividend date of this dividend is Tuesday, July 15th. AbbVie's dividend payout ratio is presently 279.15%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.